<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7145558</article-id>
    <article-id pub-id-type="pmid">31691823</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkz981</article-id>
    <article-id pub-id-type="publisher-id">gkz981</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Yunxia</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">1</xref>
        <xref ref-type="author-notes" rid="FN1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Song</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">1</xref>
        <xref ref-type="author-notes" rid="FN1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Fengcheng</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">1</xref>
        <xref ref-type="author-notes" rid="FN1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhou</surname>
          <given-names>Ying</given-names>
        </name>
        <xref ref-type="aff" rid="AFF2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Ying</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Zhengwen</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Runyuan</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhu</surname>
          <given-names>Jiang</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ren</surname>
          <given-names>Yuxiang</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tan</surname>
          <given-names>Ying</given-names>
        </name>
        <xref ref-type="aff" rid="AFF3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Qin</surname>
          <given-names>Chu</given-names>
        </name>
        <xref ref-type="aff" rid="AFF5">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Yinghong</given-names>
        </name>
        <xref ref-type="aff" rid="AFF4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Xiaoxu</given-names>
        </name>
        <xref ref-type="aff" rid="AFF4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Yuzong</given-names>
        </name>
        <!--<email>phacyz@nus.edu.sg</email>-->
        <xref ref-type="aff" rid="AFF5">5</xref>
        <xref ref-type="corresp" rid="COR2"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8069-0053</contrib-id>
        <name>
          <surname>Zhu</surname>
          <given-names>Feng</given-names>
        </name>
        <!--<email>zhufeng@zju.edu.cn</email>-->
        <xref ref-type="aff" rid="AFF1">1</xref>
        <xref ref-type="corresp" rid="COR1"/>
      </contrib>
    </contrib-group>
    <aff id="AFF1"><label>1</label><institution>College of Pharmaceutical Sciences, Zhejiang University</institution>, Hangzhou, Zhejiang 310058, <country country="CN">China</country></aff>
    <aff id="AFF2"><label>2</label><institution>Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, Zhejiang University</institution>, Hangzhou, Zhejiang 310000, <country country="CN">China</country></aff>
    <aff id="AFF3"><label>3</label><institution>State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University</institution>, Shenzhen, Guangdong 518055, <country country="CN">China</country></aff>
    <aff id="AFF4"><label>4</label><institution>School of Pharmaceutical Sciences, Chongqing University</institution>, Chongqing 401331, <country country="CN">China</country></aff>
    <aff id="AFF5"><label>5</label><institution>Bioinformatics and Drug Design Group, Department of Pharmacy, and Center for Computational Science and Engineering, National University of Singapore</institution> 117543, <country country="SG">Singapore</country></aff>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 189 8946 6518; Fax: +86 571 8820 8444; Email: <email>zhufeng@zju.edu.cn</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Yuzong Chen. Email: <email>phacyz@nus.edu.sg</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first three authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="ppub">
      <day>08</day>
      <month>1</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2019-11-06">
      <day>06</day>
      <month>11</month>
      <year>2019</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>06</day>
      <month>11</month>
      <year>2019</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
    <volume>48</volume>
    <issue>D1</issue>
    <fpage>D1031</fpage>
    <lpage>D1041</lpage>
    <history>
      <date date-type="accepted">
        <day>12</day>
        <month>10</month>
        <year>2019</year>
      </date>
      <date date-type="rev-recd">
        <day>10</day>
        <month>10</month>
        <year>2019</year>
      </date>
      <date date-type="received">
        <day>26</day>
        <month>8</month>
        <year>2019</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2019</copyright-year>
      <license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkz981.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Knowledge of therapeutic targets and early drug candidates is useful for improved drug discovery. In particular, information about target regulators and the patented therapeutic agents facilitates research regarding druggability, systems pharmacology, new trends, molecular landscapes, and the development of drug discovery tools. To complement other databases, we constructed the <italic>Therapeutic Target Database</italic> (TTD) with expanded information about (i) target-regulating microRNAs and transcription factors, (ii) target-interacting proteins, and (iii) patented agents and their targets (structures and experimental activity values if available), which can be conveniently retrieved and is further enriched with regulatory mechanisms or biochemical classes. We also updated the TTD with the recently released International Classification of Diseases ICD-11 codes and additional sets of successful, clinical trial, and literature-reported targets that emerged since the last update. TTD is accessible at <ext-link ext-link-type="uri" xlink:href="http://bidd.nus.edu.sg/group/ttd/ttd.asp">http://bidd.nus.edu.sg/group/ttd/ttd.asp</ext-link>. In case of possible web connectivity issues, two mirror sites of TTD are also constructed (<ext-link ext-link-type="uri" xlink:href="http://db.idrblab.org/ttd/">http://db.idrblab.org/ttd/</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://db.idrblab.net/ttd/">http://db.idrblab.net/ttd/</ext-link>).</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <named-content content-type="funder-name">National Key Research and Development Program of China</named-content>
          <named-content content-type="funder-identifier">10.13039/501100012166</named-content>
        </funding-source>
        <award-id>2018YFC0910500</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <named-content content-type="funder-name">National Natural Science Foundation of China</named-content>
          <named-content content-type="funder-identifier">10.13039/501100001809</named-content>
        </funding-source>
        <award-id>81872798</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <named-content content-type="funder-name">Singapore Academic Research Fund</named-content>
        </funding-source>
        <award-id>R-148-000-273-114</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <named-content content-type="funder-name">Fundamental Research Funds for Central Universities</named-content>
        </funding-source>
        <award-id>2018CDQYSG0007</award-id>
        <award-id>2018QNA7023</award-id>
        <award-id>CDJZR14468801</award-id>
        <award-id>10611CDJXZ238826</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <named-content content-type="funder-name">Innovation Project on Industrial Generic Key Technologies of Chongqing</named-content>
        </funding-source>
        <award-id>cstc2015zdcy-ztzx120003</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="11"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>The efficiency of drug discovery depends critically on the selection of appropriate candidates of therapeutic target (<xref rid="B1" ref-type="bibr">1</xref>) and targeted agent (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>). The investigation and acquired knowledge of these targets and agents are highly useful for accelerating drug discovery processes (<xref rid="B4" ref-type="bibr">4–6</xref>). Many open-access databases have provided comprehensive and complementary data of therapeutic targets. These include targets of different classes (<xref rid="B7" ref-type="bibr">7–11</xref>), drug-binding domains and targeted sites (<xref rid="B12" ref-type="bibr">12</xref>), target expression profiles in patients (<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>), activities of targeted agents (<xref rid="B15" ref-type="bibr">15–17</xref>), target-regulators (<xref rid="B18" ref-type="bibr">18–22</xref>), target-affiliated pathways (<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>), target–drug interaction networks (<xref rid="B25" ref-type="bibr">25–27</xref>), and target–disease associations (<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>). Integration of some of these data with knowledge of genetics, genomics, transcriptomics, animal models and literature enable the scoring and ranking of target–disease associations for target identification (<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>).</p>
    <p>The targets of the TTD are validated with clinical evidence of the efficacy targets of the clinically tested drugs or with patent/literature report about the therapeutic targets of research agents. Specifically, the TTD targets are grouped into classes of successful (with at least one approved drug), clinical trial (with a clinical trial drug, but without an approved drug), patent-recorded (referenced in a patent and subsequent literature), and literature-reported targets. Differences in the target selection procedure may render TTD targets that partially differ from other databases. For instance, the TTD contains 2954 human and 465 infectious species targets, and all of the 2954 human targets, yet none of the 465 infectious species targets, are in the Open Targets Platform, which contains 27 024 targets associated with human diseases (<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>).</p>
    <p>Some data content and access facilities, such as target regulators and patented agents, may be further improved. Knowledge of target regulators (e.g. microRNAs, transcription factors and interacting proteins) is useful for drug discovery tasks (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S1</xref>) such as the investigations of target druggability (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B30" ref-type="bibr">30</xref>), systems pharmacology (<xref rid="B31" ref-type="bibr">31</xref>) and the discovery of multi-target and combination therapies (<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>). The structural and activity data of patented agents are useful for such tasks as the study of discovery landscapes and opportunities (<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref>), as well as the development of artificial intelligence tools (<xref rid="B36" ref-type="bibr">36</xref>). While target regulators and patented agents can be accessed from several databases (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B18" ref-type="bibr">18–22</xref>), the data access facilities are limited because no therapeutic targets or targeted-diseases are explicitly labeled, which makes it difficult for searching data with respect to therapeutic classes and disease areas.</p>
    <p>To provide the expanded information and improved data access facilities, several major improvements were made to the Therapeutic Target Database (TTD). The <italic>first</italic> is the inclusion of two classes of target regulators, microRNAs (miRNAs) and transcription factors (TFs), for the successful (approved), clinical trial, patent-recorded and literature-reported targets in the TTD (Figure <xref ref-type="fig" rid="F1">1A</xref>). The <italic>second</italic> is the addition of the proteins directly interacting with the targets in the TTD (Figure <xref ref-type="fig" rid="F1">1A</xref>). The <italic>third</italic> is the inclusion of patented therapeutic agents and their targets searched from the patent contents and literature (Figure <xref ref-type="fig" rid="F1">1B</xref>). The <italic>fourth</italic> is the update of the recently released International Classification of Diseases codes ICD-11 for the targets in the TTD, which facilitates the access of target information using the ICD codes. The <italic>fifth</italic> is the update of the recently emerged targets and drugs since the last update (Table <xref rid="tbl1" ref-type="table">1</xref>), including the previously nonincluded classes of targeted antigens of chimeric antigen receptor T-cell (CAR-T) therapy and small molecular and peptidomimetic inhibitors of immunotherapy targets. The newly added features, together with their statistics, are summarized in <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S2</xref>.</p>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1.</label>
      <caption>
        <p>The statistics of the features newly added to the 2020 version of the TTD. (<bold>A</bold>) The inclusion of two classes of target regulators (microRNAs and transcription factors) and the addition of the proteins directly interacting with the targets; (<bold>B</bold>) the inclusion of patented therapeutic agents and their targets searched from the patent contents and literature.</p>
      </caption>
      <graphic xlink:href="gkz981fig1"/>
    </fig>
    <table-wrap id="tbl1" orientation="portrait" position="float">
      <label>Table 1.</label>
      <caption>
        <p>Accumulation of drugs and their corresponding targets in the latest version and previous versions of the TTD</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1"/>
            <th rowspan="1" colspan="1">2020</th>
            <th rowspan="1" colspan="1">2018</th>
            <th rowspan="1" colspan="1">2016</th>
            <th rowspan="1" colspan="1">2014</th>
            <th rowspan="1" colspan="1">2012</th>
            <th rowspan="1" colspan="1"/>
            <th rowspan="1" colspan="1">2020</th>
            <th rowspan="1" colspan="1">2018</th>
            <th rowspan="1" colspan="1">2016</th>
            <th rowspan="1" colspan="1">2014</th>
            <th rowspan="1" colspan="1">2012</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">
              <bold>All Targets</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>3419</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>3101</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>2589</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>2316</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>1981</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>All Drugs</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>37 316</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>29 570</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>27 165</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>20 006</bold>
            </td>
            <td rowspan="1" colspan="1">
              <bold>17 816</bold>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Successful</td>
            <td rowspan="1" colspan="1">461</td>
            <td rowspan="1" colspan="1">445</td>
            <td rowspan="1" colspan="1">397</td>
            <td rowspan="1" colspan="1">388</td>
            <td rowspan="1" colspan="1">364</td>
            <td rowspan="1" colspan="1">Approved</td>
            <td rowspan="1" colspan="1">2649</td>
            <td rowspan="1" colspan="1">2544</td>
            <td rowspan="1" colspan="1">2071</td>
            <td rowspan="1" colspan="1">2003</td>
            <td rowspan="1" colspan="1">1540</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Clinical Trial</td>
            <td rowspan="1" colspan="1">1191</td>
            <td rowspan="1" colspan="1">1121</td>
            <td rowspan="1" colspan="1">723</td>
            <td rowspan="1" colspan="1">461</td>
            <td rowspan="1" colspan="1">286</td>
            <td rowspan="1" colspan="1">Clinical Trial</td>
            <td rowspan="1" colspan="1">9465</td>
            <td rowspan="1" colspan="1">8103</td>
            <td rowspan="1" colspan="1">7291</td>
            <td rowspan="1" colspan="1">3147</td>
            <td rowspan="1" colspan="1">1423</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Patent-Recorded</td>
            <td rowspan="1" colspan="1">207</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">Patented</td>
            <td rowspan="1" colspan="1">5,059</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">0</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Literature-Reported</td>
            <td rowspan="1" colspan="1">1560</td>
            <td rowspan="1" colspan="1">1535</td>
            <td rowspan="1" colspan="1">1469</td>
            <td rowspan="1" colspan="1">1467</td>
            <td rowspan="1" colspan="1">1331</td>
            <td rowspan="1" colspan="1">Experimental</td>
            <td rowspan="1" colspan="1">20 143</td>
            <td rowspan="1" colspan="1">18 923</td>
            <td rowspan="1" colspan="1">17 803</td>
            <td rowspan="1" colspan="1">14 856</td>
            <td rowspan="1" colspan="1">14 853</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="T1TFN1">
          <p>Patented drugs and their corresponding targets were, for the first time, collected and integrated into this version of the TTD.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </sec>
  <sec id="SEC2">
    <title>TARGET REGULATORS</title>
    <sec id="SEC2-1">
      <title>Target-regulating MicroRNAs</title>
      <p>MicroRNAs (miRNAs) are reported to negatively regulate the expression of ∼30% of human genes. miRNA has demonstrated profound pharmacological/pharmacokinetic implications in the regulation of therapeutic targets, drug metabolism enzymes or transporters (<xref rid="B37" ref-type="bibr">37</xref>). For example, miR-125b inhibits the expression of vitamin D receptor (therapeutic target of the drug calcitriol), which results in the reduced efficacy of calcitriol by a lowered target level (<xref rid="B38" ref-type="bibr">38</xref>); another study has shown that the overexpression of miR-24 downregulates dihydrofolate reductase (target of chemotherapeutic drug methotrexate), which induces methotrexate resistance (<xref rid="B39" ref-type="bibr">39</xref>). Thus, the information regarding target-regulating miRNAs is helpful for studying the regulation of targeted therapeutics in individual patients (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B40" ref-type="bibr">40</xref>) and exploring multi-target treatment strategies (<xref rid="B41" ref-type="bibr">41</xref>).</p>
      <p>Since the target-regulating miRNA data were largely dispersed in the literature, the PubMed database was systematically searched using the combination of the keywords ‘microRNA’/‘micro-RNA’/‘mi-RNA’/‘miR’/‘miRNA’/ ‘hsa-miR’/‘hsa-let’ and the names/synonyms of TTD targets. The collected data include the following: (i) the names and sequences of mature miRNAs and (ii) the experiments confirming the regulation of a studied target by certain miRNAs. The collected experiments include reporter assay, quantitative polymerase chain reaction (qPCR), <italic>in situ</italic> hybridization, northern blot, and so on (<xref rid="B42" ref-type="bibr">42</xref>,<xref rid="B43" ref-type="bibr">43</xref>). Some of the above experiments (e.g. western blot and reporter assay) are typically applied methods for discovering protein-regulating miRNAs, and some methods (e.g. qPCR, <italic>in situ</italic> hybridization and northern blot) have been frequently used to identify miRNAs coexpressed with the genes of therapeutic targets (<xref rid="B42" ref-type="bibr">42–45</xref>). These literature-reported regulation mechanisms are provided in the TTD.</p>
      <p>The latest version of the TTD collected 179 successful, 298 clinical trial, 62 patent-recorded and 330 literature-reported targets that are regulated by 587 miRNAs, involving 3707 miRNA and target regulation pairs. The confidence level of an experimentally observed regulation can be tentatively measured by the number of published experimental sources of evidence (<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>). Thus, an evidence score (<italic>E-score</italic>, the number of published research articles of experimental evidence) was defined for the tentative measurement of the confidence level of target-regulating miRNAs. The target-regulating miRNAs are listed with respect to their <italic>E-scores</italic>. A typical webpage providing the target-regulating miRNA is shown in Figure <xref ref-type="fig" rid="F2">2</xref>.</p>
      <fig id="F2" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>A typical page in the TTD providing target-regulating microRNA information. The detailed information on microRNA sequences, supporting experiments, and other targets regulated by the collected microRNA. The target-regulating microRNAs are listed on the TTD webpage with respect to the <italic>E-scores</italic>, which were derived using the number of papers describing the experimental evidence. The details of each microRNA can be found by clicking the ‘miRNA Info’ button.</p>
        </caption>
        <graphic xlink:href="gkz981fig2"/>
      </fig>
    </sec>
    <sec id="SEC2-2">
      <title>Target-regulating transcription factors</title>
      <p>Transcription factors (TFs) regulate the expression of genes by controlling transcription of genetic information from DNA to messenger RNA. TFs that regulate the therapeutically relevant genes have been explored as the targets of approved drugs (<xref rid="B48" ref-type="bibr">48</xref>). For example, both premarin (for treating osteoporosis) and tamoxifen (for treating breast cancer) target the transcription factor estrogen receptor (ER), which regulates the expression of estrogen-responsive genes that control both osteoporosis and breast cancer, thereby manifesting their osteoporosis-preventive and anticancer effects (<xref rid="B48" ref-type="bibr">48</xref>). Although many TFs are important disease regulators, and thus potential therapeutic targets, many of them have been considered to be undruggable, partly owing to the large protein–protein interaction interfaces or lack of deep protein pockets for small molecule drug binding (<xref rid="B49" ref-type="bibr">49</xref>). Progress has been made for drug discovery against the targets previously considered to be undruggable (<xref rid="B50" ref-type="bibr">50</xref>). Thus, it is useful to provide the data with respect to target-regulating TFs for facilitating future efforts in targeting TFs.</p>
      <p>Target-regulating TF data were collected by comprehensively searching the PubMed database using the combinations of the keywords ‘transcription factor’/‘TF’/‘DNA-binding factor’/‘DNA-binding’/‘transcription regulation’/‘promoter’/‘enhancer’/‘silencer’ and names/synonyms of each therapeutic target in the TTD. In total, 55 successful, 61 clinical trial, 6 patent-recorded and 31 literature-reported targets regulated by 135 TFs were collected. These collected data include the following: (i) the names and sequences of TFs regulating each target, (ii) TF classifications (superclass, class, family and subfamily) defined by TRANSFAC (<xref rid="B51" ref-type="bibr">51</xref>,<xref rid="B52" ref-type="bibr">52</xref>) and (iii) the experiments used to confirm the regulation of a studied target by TFs. These experiments include electrophoretic mobility shift assays (<xref rid="B53" ref-type="bibr">53</xref>), chromatin immunoprecipitations (<xref rid="B54" ref-type="bibr">54</xref>), DNase footprinting assays (<xref rid="B55" ref-type="bibr">55</xref>), and so on. They have been used for probing the direct binding of a TF to the promoter, enhancer or silencer region of a target gene, thus leading to the initiation (<xref rid="B56" ref-type="bibr">56</xref>), increase (<xref rid="B57" ref-type="bibr">57</xref>) or repression of the transcription of the studied gene (<xref rid="B58" ref-type="bibr">58</xref>), respectively. These literature-reported regulation mechanisms are provided in the TTD. The target-regulating TFs are listed in the TTD with respect to their <italic>E-scores</italic>, which were derived using the numbers of papers describing the experimental evidence. Moreover, the genes coregulated by each target-regulating TF are provided in the TTD and grouped by biochemical class (Figure <xref ref-type="fig" rid="F3">3</xref>).</p>
      <fig id="F3" orientation="portrait" position="float">
        <label>Figure 3.</label>
        <caption>
          <p>A typical page in the TTD providing information about target-regulating transcription factors (TFs). The target-regulating TFs are listed on the TTD webpage with respect to their <italic>E-scores</italic>, which were derived using the number of papers describing the experimental evidence. The genes coregulated by each target-regulating TF are provided in the TTD and grouped using biochemical classes (GPCR, peptidase, virus penetration channel, <italic>etc</italic>.).</p>
        </caption>
        <graphic xlink:href="gkz981fig3"/>
      </fig>
    </sec>
  </sec>
  <sec id="SEC3">
    <title>TARGET-INTERACTING PROTEINS</title>
    <p>Knowledge of target-protein interactions is important for network pharmacology studies (<xref rid="B59" ref-type="bibr">59</xref>) and target druggability assessments (<xref rid="B60" ref-type="bibr">60</xref>,<xref rid="B61" ref-type="bibr">61</xref>). Particularly, the analysis of the human target-protein network topological properties (derived from the human target-protein interaction data) has revealed that successful targets are more highly connected to other proteins and have higher network betweenness (the number of times a studied protein appears in the shortest path between two other proteins in network divided by the total number of protein pairs) than other proteins (<xref rid="B60" ref-type="bibr">60</xref>); the human target-protein network topological features and human systems druggability characteristics of 89 innovative targets of the first-in-class drugs approved from 2004 to 2017 have led to a simple rule describing the clinical trial progression speed of innovative drug targets (<xref rid="B50" ref-type="bibr">50</xref>), which states that the human target entering clinical trials may progress more speedily through the trials if it has no violations of the following criteria: (i) two human target-protein network topological properties are within specified values (neighborhood connectivity &lt;15 and degree &lt;15) and (ii) three system druggability properties are within specified ranges (affiliated with &lt;5 human signal pathways, distributed in &lt;5 human tissues and similar to &lt;15 human similarity proteins outside the target family) (<xref rid="B50" ref-type="bibr">50</xref>). The degree is the total number of interacting proteins of a given target, and neighborhood connectivity of a given target denotes the average number of human interacting proteins of its own neighbors/interacting proteins. These and other studies have shown that the target-interacting protein information is essential for facilitating the pharmacological, druggability and clinical investigations of therapeutic targets.</p>
    <p>The target-interacting protein data were collected from <italic>BioGrid</italic>, which provides experimentally documented human protein physical interactions (<xref rid="B62" ref-type="bibr">62</xref>) based on evidence from such experimental methods as affinity capture-western blotting, colocalization studies, yeast two-hybrid screens, fluorescence resonance energy transfer, protein-fragment complementation assays, reconstituted complexes, far western blotting, proximity label-MS, and so on. Only the target-interacting proteins validated by no less than two experiments were collected, and the numbers of papers describing the experimental evidence were directly used as the evidence score (<italic>E-score</italic>). Overall, there are 139 successful, 276 clinical trial, 86 patent-recorded and 398 literature-reported targets with 2458 interacting proteins in the TTD, involving 6975 pairs of target-protein interactions. Moreover, due to the high number of target-interacting proteins (32.8% of the targets in the TTD interact with &gt;10 proteins), it was difficult to produce a complete interaction profile of a target by simply crosslinking to other protein interaction databases. Thus, the target-interacting proteins are provided in groups of biochemical classes (GPCR, peptidase, virus penetration channel, etc.) on the webpage (Figure <xref ref-type="fig" rid="F4">4</xref>), and the target-interacting proteins within each class are listed with respect to their <italic>E-scores</italic>.</p>
    <fig id="F4" orientation="portrait" position="float">
      <label>Figure 4.</label>
      <caption>
        <p>A typical page in the TTD providing information about target-interacting proteins. The target-interacting proteins are provided in groups of biochemical classes (GPCR, peptidase, virus penetration channel, etc.) on a webpage, and the target-interacting proteins within each class are listed with respect to their <italic>E-scores</italic>. Detailed information of each interacting protein or target can also be found by clicking the ‘Interacting Protein Info’ or ‘Target Info’ button.</p>
      </caption>
      <graphic xlink:href="gkz981fig4"/>
    </fig>
  </sec>
  <sec id="SEC4">
    <title>PATENTED THERAPEUTIC AGENTS AND THEIR TARGETS</title>
    <p>Patented therapeutic agents represent special classes of bioactive molecules in the stage of early drug discovery. These agents differ from other bioactive molecules with respect to the perception of high development potential by drug developers, which makes them good indicators of drug development trends, emerging/evolving molecular landscapes and collaborative opportunities in the early developmental stage (<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref>). Thus, there is a particular need for expanding the coverage of the target and drug data to cover the patented therapeutic agents and their targets. The targets of patented therapeutic agents are referred to here as the patent-recorded targets.</p>
    <p>The patented therapeutic agents and their corresponding targets were searched and processed by the following procedure: <italic>first</italic>, all papers published during the period of 2004–2018 in <italic>Expert Opinion on Therapeutic Patents</italic> were manually reviewed; <italic>second</italic>, those key data describing the collected agents together with their targets were recorded, which included the following: (i) the title, abstract, applicants, issued ID and patent agency, (ii) potential therapeutic indications, 3D structures, and compound classes of patented agents and (iii) experimental binding activities (if available) between patented agents and their corresponding targets. In total, 5059 patented agents (belonging to 571 compound classes) included in 3145 patents issued by very diverse intellectual property authorities (World Intellectual Property Organization, United States Patent and Trademark Office, European Patent Office, National Intellectual Property Administration of China, etc.) were collected. Based on a fingerprint-based <italic>Tanimoto</italic> search, 86.7% of the patented agents collected in the TTD are different from, and 85.4% of the agents are of remote to intermediate similarity to, the patented agents in the databases with explicit target data (<xref rid="B17" ref-type="bibr">17</xref>). Therefore, the TTD complements the available database in collectively providing comprehensive information about the patented agents.</p>
    <p>The TTD patented agents target 215 successful, 236 clinical trial and 207 patent-recorded targets. Among those patented agents, 4774 include 2D/3D structures provided in corresponding papers. These structures are manually drawn using <italic>ChemDraw</italic> (<xref rid="B63" ref-type="bibr">63</xref>) and can be viewed and downloaded from the TTD. Moreover, 3388 of the 5,059 agents include experimental target binding activity data and 2215 of the 5059 agents were mapped with PubChem IDs (<xref rid="B11" ref-type="bibr">11</xref>) according to a structural search (<italic>Tanimoto coefficient</italic> (<xref rid="B64" ref-type="bibr">64</xref>) between molecular fingerprints equals to one) and a subsequent visual inspection of all matches. The remaining nonmatched agents were not found in PubChem. A typical webpage of the patented agents in the TTD is shown in Figure <xref ref-type="fig" rid="F5">5</xref>.</p>
    <fig id="F5" orientation="portrait" position="float">
      <label>Figure 5.</label>
      <caption>
        <p>A typical page in the TTD providing information about the targets of patented therapeutic agents. The information included the patent details (patent office, title, abstract, etc.), representative patented drugs, and their corresponding activities with respect to their targets. Detailed information of each drug or target can also be found by clicking the ‘Drug Info’ or ‘Target Info’ button.</p>
      </caption>
      <graphic xlink:href="gkz981fig5"/>
    </fig>
  </sec>
  <sec id="SEC5">
    <title>THE INTERNATIONAL CLASSIFICATION OF DISEASE ICD-11 CODES</title>
    <p>The International Classification of Diseases (ICD) is a health statistics and diagnostics coding tool for describing human disease conditions (<xref rid="B65" ref-type="bibr">65</xref>), and it has been applied to other applications such as the development of artificial intelligence diagnostic tools (<xref rid="B66" ref-type="bibr">66</xref>). The 11th revision of ICD (ICD-11) launched in 2018 (<xref rid="B65" ref-type="bibr">65</xref>), which accomplished substantial improvement upon its previous version (ICD-10), with 55 000 unique codes compared with 14 400 for ICD-10. In addition to the more detailed description of the disease conditions, there are significant changes in the coding system. These include new code chapters for sexual health and traditional medicines, stroke being listed as a neurological disorder instead of a circulatory disorder, allergies being coded under immune system disease, and HIV infection being described as a chronic condition. Due to the significant changes in ICD codes, the TTD was updated with ICD-11 codes while retaining the original ICD-9 and ICD-10 codes that were introduced in previous TTD versions (<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B67" ref-type="bibr">67</xref>). Users can use a pull-down manual to search TTD data by means of an ICD-11 code menu.</p>
  </sec>
  <sec id="SEC6">
    <title>SPECIAL CLASSES OF TARGETS OF IMMUNOTHERAPY AGENTS</title>
    <p>New classes of immunotherapy agents have emerged. One class is CAR T-cell therapy, which is a form of immunotherapy that uses specially altered T-cells to treat cancer (<xref rid="B68" ref-type="bibr">68</xref>). A sample of a patient's T cells, collected from the blood, are modified to produce chimeric antigen receptors (CARs) on their surfaces. When these CAR-T cells are reinfused into patients, the new receptors on these cells enable them to bind to specific antigens on the patients’ cancer cells, thereby killing them. Knowledge regarding the target antigens of clinically used or tested CAR-T therapy is thus very useful for the study and discovery of this special class of agent. Therefore, the antigens of approved and clinical trial CAR-T therapies were systematically searched based on the following procedures: <italic>first</italic>, approved CAR-T therapies were collected from the February issue of <italic>Nature Reviews Drug Discovery</italic> (<xref rid="B69" ref-type="bibr">69</xref>), and the CAR-T therapies in clinical trials were obtained from the official websites or recent reports of 122 pharmaceutical companies/research institutes/hospitals; <italic>second</italic>, the clinical status of each CAR-T therapy was further validated by the <italic>ClinicalTrials.gov</italic> (<xref rid="B70" ref-type="bibr">70</xref>), and the corresponding disease indications and NCT numbers were confirmed; <italic>third</italic>, the target antigen of each CAR-T therapy was identified using <italic>ClinicalTrials.gov</italic> and PubMed. In total, 2 approved, 4 phase III, 166 phase II and 187 phase I CAR-T therapies for treating of 92 diseases were collected, which targeted 17 successful and 35 clinical trial targets in the TTD.</p>
    <p>The second class of immunotherapy agents include small molecular and peptidomimetic immune checkpoint inhibitors (<xref rid="B71" ref-type="bibr">71</xref>). Although the monoclonal antibody immune checkpoint inhibitors are highly successful in cancer treatment, they present such problems as difficulty in penetrating into tumors and the need for slow intravenous infusion treatment (<xref rid="B72" ref-type="bibr">72</xref>). These problems may be partially overcome by the introduction of small molecule drugs. Successful efforts have been directed at discovering small molecular and peptidomimetic immune checkpoint inhibitors (<xref rid="B71" ref-type="bibr">71</xref>). Thus, PubMed was systematically searched using such combinations as the keywords ‘small molecular inhibitor’/‘small molecular agent’/‘peptidomimetic agent’/‘peptidomimetics’/‘peptidomimetic inhibitors’ and ‘immune checkpoint’. In total, 2 clinical trial, 121 patented, 2 preclinical, and 56 investigative immunotherapies for treating five classes of disease were collected.</p>
  </sec>
  <sec id="SEC7">
    <title>ACCESS FACILITIES FOR THE NEWLY ADDED FEATURES</title>
    <p>The addition of new information has made the TTD webpages too crowded, which hinders the ability of users to find the preferred information. To resolve this problem, the TTD target webpage was redesigned by categorizing the information into multiple groups: (i) target general information, (ii) drugs and their modes of actions, (iii) target regulators, (iv) target profiles in patients, (v) target affiliated pathways and (vi) target-related models and studies (Figure <xref ref-type="fig" rid="F6">6</xref>). The information in each group is itemized within a small block on the webpage, and users can access detailed information by clicking each item. The newly added features of target regulators (miRNA and TF), target-interacting proteins and the targets of patented therapeutic agents can be accessed via the ‘Target Group’ manual bar, and the small molecular and peptidomimetic inhibitors of immunotherapy targets and the patented therapeutic agents are provided under the ‘Drug Group’ manual bar. Figure <xref ref-type="fig" rid="F1">1</xref> provides a typical page in the TTD describing the information about target-regulating miRNAs. Figure <xref ref-type="fig" rid="F2">2</xref> shows the page illustrating the data regarding target-interacting proteins. Figure <xref ref-type="fig" rid="F3">3</xref> exhibits the page showing the data of patented therapeutic agents together with their corresponding targets. The database platform <italic>Drupal</italic> was employed in the TTD to enhance data storage and extraction. Extensively accelerated data access and transmission were achieved via the cloud platform of <italic>Aliyun</italic> located in Silicon Valley.</p>
    <fig id="F6" orientation="portrait" position="float">
      <label>Figure 6.</label>
      <caption>
        <p>A redesigned TTD target webpage categorizing the information into the groups of (<xref rid="B1" ref-type="bibr">i</xref>) target general information, (<xref rid="B2" ref-type="bibr">ii</xref>) drugs and modes of action, (<xref rid="B3" ref-type="bibr">i</xref>ii) target regulators, (<xref rid="B4" ref-type="bibr">iv</xref>) target profiles in patients, (<xref rid="B5" ref-type="bibr">v</xref>) target affiliated pathways and (<xref rid="B6" ref-type="bibr">vi</xref>) target-related models and studies.</p>
      </caption>
      <graphic xlink:href="gkz981fig6"/>
    </fig>
  </sec>
  <sec id="SEC8">
    <title>CONCLUDING REMARKS</title>
    <p>Intensive drug research and development efforts have led to extensively expanded knowledge of biological systems (<xref rid="B73" ref-type="bibr">73</xref>,<xref rid="B74" ref-type="bibr">74</xref>), disease processes (<xref rid="B75" ref-type="bibr">75</xref>,<xref rid="B76" ref-type="bibr">76</xref>) and the mechanisms of targeted therapeutics (<xref rid="B77" ref-type="bibr">77–79</xref>). The expanded knowledge has facilitated the successful development of new therapies (<xref rid="B68" ref-type="bibr">68</xref>), and it will further facilitate the discoveries of such therapeutic approaches as polypharmacology (<xref rid="B80" ref-type="bibr">80</xref>) and RNA therapeutics (<xref rid="B81" ref-type="bibr">81</xref>). For better serving the drug discovery communities, additional efforts have been directed at further enriching the TTD and other established databases with comprehensive information about drugs, targets, and their regulation.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sup1">
      <label>gkz981_Supplemental_File</label>
      <media xlink:href="gkz981_supplemental_file.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec id="SEC9">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkz981#supplementary-data">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC10">
    <title>FUNDING</title>
    <p>National Key R&amp;D Program of China [2018YFC0910500]; National Natural Science Foundation of China [81872798]; Singapore Academic Research Fund grant [R-148-000-273-114]; Fundamental Research Funds for Central Universities [2018CDQYSG0007, 2018QNA7023, CDJZR14468801, 10611CDJXZ238826]; Innovation Project on Industrial Generic Key Technologies of Chongqing [cstc2015zdcy-ztzx120003]. Funding for open access charge: National Key R &amp; D Program of China [2018YFC0910500]; National Natural Science Foundation of China [81872798].</p>
    <p><italic>Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ursu</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Bento</surname><given-names>A.P.</given-names></name>, <name name-style="western"><surname>Donadi</surname><given-names>R.S.</given-names></name>, <name name-style="western"><surname>Bologa</surname><given-names>C.G.</given-names></name>, <name name-style="western"><surname>Karlsson</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Al-Lazikani</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Hersey</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name><etal>et al</etal>.</person-group><article-title>A comprehensive map of molecular drug targets</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2017</year>; <volume>16</volume>:<fpage>19</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">27910877</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munos</surname><given-names>B.</given-names></name></person-group><article-title>Lessons from 60 years of pharmaceutical innovation</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2009</year>; <volume>8</volume>:<fpage>959</fpage>–<lpage>968</lpage>.<pub-id pub-id-type="pmid">19949401</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name></person-group><article-title>Using reverse docking for target identification and its applications for drug discovery</article-title>. <source>Expert Opin. Drug Discov.</source><year>2016</year>; <volume>11</volume>:<fpage>707</fpage>–<lpage>715</lpage>.<pub-id pub-id-type="pmid">27186904</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waring</surname><given-names>M.J.</given-names></name>, <name name-style="western"><surname>Arrowsmith</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Leach</surname><given-names>A.R.</given-names></name>, <name name-style="western"><surname>Leeson</surname><given-names>P.D.</given-names></name>, <name name-style="western"><surname>Mandrell</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Owen</surname><given-names>R.M.</given-names></name>, <name name-style="western"><surname>Pairaudeau</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Pennie</surname><given-names>W.D.</given-names></name>, <name name-style="western"><surname>Pickett</surname><given-names>S.D.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal>et al</etal>.</person-group><article-title>An analysis of the attrition of drug candidates from four major pharmaceutical companies</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2015</year>; <volume>14</volume>:<fpage>475</fpage>–<lpage>486</lpage>.<pub-id pub-id-type="pmid">26091267</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keseru</surname><given-names>G.M.</given-names></name>, <name name-style="western"><surname>Makara</surname><given-names>G.M.</given-names></name></person-group><article-title>The influence of lead discovery strategies on the properties of drug candidates</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2009</year>; <volume>8</volume>:<fpage>203</fpage>–<lpage>212</lpage>.<pub-id pub-id-type="pmid">19247303</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>C.J.</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>L.Y.</given-names></name>, <name name-style="western"><surname>Yap</surname><given-names>C.W.</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>Z.L.</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>Z.W.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.Z.</given-names></name></person-group><article-title>Therapeutic targets: progress of their exploration and investigation of their characteristics</article-title>. <source>Pharmacol. Rev.</source><year>2006</year>; <volume>58</volume>:<fpage>259</fpage>–<lpage>279</lpage>.<pub-id pub-id-type="pmid">16714488</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.H.</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>C.Y.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.Z.</given-names></name></person-group><article-title>Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D1069</fpage>–<lpage>D1074</lpage>.<pub-id pub-id-type="pmid">26578601</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendez</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Bento</surname><given-names>A.P.</given-names></name>, <name name-style="western"><surname>Chambers</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>De Veij</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Felix</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Magarinos</surname><given-names>M.P.</given-names></name>, <name name-style="western"><surname>Mosquera</surname><given-names>J.F.</given-names></name>, <name name-style="western"><surname>Mutowo</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Nowotka</surname><given-names>M.</given-names></name><etal>et al</etal>.</person-group><article-title>ChEMBL: towards direct deposition of bioassay data</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D930</fpage>–<lpage>D940</lpage>.<pub-id pub-id-type="pmid">30398643</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>D.S.</given-names></name>, <name name-style="western"><surname>Feunang</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>A.C.</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>E.J.</given-names></name>, <name name-style="western"><surname>Marcu</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Sajed</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sayeeda</surname><given-names>Z.</given-names></name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papadatos</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Davies</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Dedman</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Chambers</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Siddle</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Koks</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Irvine</surname><given-names>S.A.</given-names></name>, <name name-style="western"><surname>Pettersson</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Goncharoff</surname><given-names>N.</given-names></name><etal>et al</etal>.</person-group><article-title>SureChEMBL: a large-scale, chemically annotated patent document database</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D1220</fpage>–<lpage>D1228</lpage>.<pub-id pub-id-type="pmid">26582922</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Gindulyte</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Shoemaker</surname><given-names>B.A.</given-names></name>, <name name-style="western"><surname>Thiessen</surname><given-names>P.A.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><etal>et al</etal>.</person-group><article-title>PubChem 2019 update: improved access to chemical data</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D1102</fpage>–<lpage>D1109</lpage>.<pub-id pub-id-type="pmid">30371825</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Brylinski</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Kurgan</surname><given-names>L.</given-names></name></person-group><article-title>PDID: database of molecular-level putative protein-drug interactions in the structural human proteome</article-title>. <source>Bioinformatics</source>. <year>2016</year>; <volume>32</volume>:<fpage>579</fpage>–<lpage>586</lpage>.<pub-id pub-id-type="pmid">26504143</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name></person-group><article-title>dbDEPC 3.0: the database of differentially expressed proteins in human cancer with multi-level annotation and drug indication</article-title>. <source>Database (Oxford)</source>. <year>2018</year>; <volume>2018</volume>:<fpage>bay015</fpage>.</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>dbDEPC: a database of differentially expressed proteins in human cancers</article-title>. <source>Nucleic Acids Res.</source><year>2010</year>; <volume>38</volume>:<fpage>D658</fpage>–<lpage>D664</lpage>.<pub-id pub-id-type="pmid">19900968</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harding</surname><given-names>S.D.</given-names></name>, <name name-style="western"><surname>Sharman</surname><given-names>J.L.</given-names></name>, <name name-style="western"><surname>Faccenda</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Southan</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Pawson</surname><given-names>A.J.</given-names></name>, <name name-style="western"><surname>Ireland</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>A.J.G.</given-names></name>, <name name-style="western"><surname>Bruce</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>S.P.H.</given-names></name>, <name name-style="western"><surname>Anderton</surname><given-names>S.</given-names></name><etal>et al</etal>.</person-group><article-title>The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1091</fpage>–<lpage>D1106</lpage>.<pub-id pub-id-type="pmid">29149325</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ursu</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bologa</surname><given-names>C.G.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J.J.</given-names></name>, <name name-style="western"><surname>Mathias</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Stathias</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>D.T.</given-names></name>, <name name-style="western"><surname>Schurer</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>T.</given-names></name></person-group><article-title>DrugCentral 2018: an update</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D963</fpage>–<lpage>D970</lpage>.<pub-id pub-id-type="pmid">30371892</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilson</surname><given-names>M.K.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Baitaluk</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Nicola</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Hwang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Chong</surname><given-names>J.</given-names></name></person-group><article-title>BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D1045</fpage>–<lpage>D1053</lpage>.<pub-id pub-id-type="pmid">26481362</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karagkouni</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Paraskevopoulou</surname><given-names>M.D.</given-names></name>, <name name-style="western"><surname>Chatzopoulos</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Vlachos</surname><given-names>I.S.</given-names></name>, <name name-style="western"><surname>Tastsoglou</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kanellos</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Papadimitriou</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Kavakiotis</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Maniou</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Skoufos</surname><given-names>G.</given-names></name><etal>et al</etal>.</person-group><article-title>DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D239</fpage>–<lpage>D245</lpage>.<pub-id pub-id-type="pmid">29156006</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Qu</surname><given-names>L.H.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J.H.</given-names></name></person-group><article-title>starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>; <volume>42</volume>:<fpage>D92</fpage>–<lpage>D97</lpage>.<pub-id pub-id-type="pmid">24297251</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>C.H.</given-names></name>, <name name-style="western"><surname>Shrestha</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>C.D.</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>N.W.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>Y.L.</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>K.W.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>W.C.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>T.H.</given-names></name>, <name name-style="western"><surname>Tu</surname><given-names>S.J.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>W.H.</given-names></name><etal>et al</etal>.</person-group><article-title>miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D296</fpage>–<lpage>D302</lpage>.<pub-id pub-id-type="pmid">29126174</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rangasamy</surname><given-names>S.B.</given-names></name>, <name name-style="western"><surname>Jana</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Corbett</surname><given-names>G.T.</given-names></name>, <name name-style="western"><surname>Kundu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Chandra</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Mondal</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Dasarathi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Mufson</surname><given-names>E.J.</given-names></name>, <name name-style="western"><surname>Mishra</surname><given-names>R.K.</given-names></name><etal>et al</etal>.</person-group><article-title>Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer's pathology</article-title>. <source>J. Clin. Invest.</source><year>2018</year>; <volume>128</volume>:<fpage>4297</fpage>–<lpage>4312</lpage>.<pub-id pub-id-type="pmid">29990310</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.P.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Miao</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name></person-group><article-title>RegNetwork: an integrated database of transcriptional and post-transcriptional regulatory networks in human and mouse</article-title>. <source>Database (Oxford)</source>. <year>2015</year>; <volume>2015</volume>:<fpage>bav095</fpage>.<pub-id pub-id-type="pmid">26424082</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Furumichi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Morishima</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Tanabe</surname><given-names>M.</given-names></name></person-group><article-title>New approach for understanding genome variations in KEGG</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D590</fpage>–<lpage>D595</lpage>.<pub-id pub-id-type="pmid">30321428</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name></person-group><article-title>ccmGDB: a database for cancer cell metabolism genes</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D959</fpage>–<lpage>D968</lpage>.<pub-id pub-id-type="pmid">26519468</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Southan</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sharman</surname><given-names>J.L.</given-names></name>, <name name-style="western"><surname>Benson</surname><given-names>H.E.</given-names></name>, <name name-style="western"><surname>Faccenda</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Pawson</surname><given-names>A.J.</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>S.P.</given-names></name>, <name name-style="western"><surname>Buneman</surname><given-names>O.P.</given-names></name>, <name name-style="western"><surname>Davenport</surname><given-names>A.P.</given-names></name>, <name name-style="western"><surname>McGrath</surname><given-names>J.C.</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>J.A.</given-names></name><etal>et al</etal>.</person-group><article-title>The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D1054</fpage>–<lpage>D1068</lpage>.<pub-id pub-id-type="pmid">26464438</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gohlke</surname><given-names>B.O.</given-names></name>, <name name-style="western"><surname>Nickel</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Otto</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Dunkel</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Preissner</surname><given-names>R.</given-names></name></person-group><article-title>CancerResource–updated database of cancer-relevant proteins, mutations and interacting drugs</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D932</fpage>–<lpage>D937</lpage>.<pub-id pub-id-type="pmid">26590406</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.H.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>C.Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.X.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Tu</surname><given-names>G.</given-names></name><etal>et al</etal>.</person-group><article-title>Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1121</fpage>–<lpage>D1127</lpage>.<pub-id pub-id-type="pmid">29140520</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koscielny</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>An</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Carvalho-Silva</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Cham</surname><given-names>J.A.</given-names></name>, <name name-style="western"><surname>Fumis</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Gasparyan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Hasan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Karamanis</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Maguire</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Papa</surname><given-names>E.</given-names></name><etal>et al</etal>.</person-group><article-title>Open Targets: a platform for therapeutic target identification and validation</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>; <volume>45</volume>:<fpage>D985</fpage>–<lpage>D994</lpage>.<pub-id pub-id-type="pmid">27899665</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho-Silva</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Pierleoni</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Pignatelli</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ong</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Fumis</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Karamanis</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Carmona</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Faulconbridge</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hercules</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>McAuley</surname><given-names>E.</given-names></name><etal>et al</etal>.</person-group><article-title>Open Targets Platform: new developments and updates two years on</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D1056</fpage>–<lpage>D1065</lpage>.<pub-id pub-id-type="pmid">30462303</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finan</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kruger</surname><given-names>F.A.</given-names></name>, <name name-style="western"><surname>Lumbers</surname><given-names>R.T.</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Engmann</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Galver</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Kelley</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Karlsson</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Santos</surname><given-names>R.</given-names></name><etal>et al</etal>.</person-group><article-title>The druggable genome and support for target identification and validation in drug development</article-title>. <source>Sci. Transl. Med.</source><year>2017</year>; <volume>9</volume>:<fpage>eaag1166</fpage>.<pub-id pub-id-type="pmid">28356508</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Iyengar</surname><given-names>R.</given-names></name></person-group><article-title>Systems pharmacology: network analysis to identify multiscale mechanisms of drug action</article-title>. <source>Annu. Rev. Pharmacol. Toxicol.</source><year>2012</year>; <volume>52</volume>:<fpage>505</fpage>–<lpage>521</lpage>.<pub-id pub-id-type="pmid">22235860</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>Z.W.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.X.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.Z.</given-names></name></person-group><article-title>Mechanisms of drug combinations: interaction and network perspectives</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2009</year>; <volume>8</volume>:<fpage>111</fpage>–<lpage>128</lpage>.<pub-id pub-id-type="pmid">19180105</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Csermely</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Agoston</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Pongor</surname><given-names>S.</given-names></name></person-group><article-title>The efficiency of multi-target drugs: the network approach might help drug design</article-title>. <source>Trends Pharmacol. Sci.</source><year>2005</year>; <volume>26</volume>:<fpage>178</fpage>–<lpage>182</lpage>.<pub-id pub-id-type="pmid">15808341</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaabani</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Huizinga</surname><given-names>H.P.S.</given-names></name>, <name name-style="western"><surname>Butera</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Kouchi</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Guzik</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Magiera-Mularz</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Holak</surname><given-names>T.A.</given-names></name>, <name name-style="western"><surname>Domling</surname><given-names>A.</given-names></name></person-group><article-title>A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)</article-title>. <source>Expert Opin. Ther. Pat.</source><year>2018</year>; <volume>28</volume>:<fpage>665</fpage>–<lpage>678</lpage>.<pub-id pub-id-type="pmid">30107136</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grandjean</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Charpiot</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Pena</surname><given-names>C.A.</given-names></name>, <name name-style="western"><surname>Peitsch</surname><given-names>M.C.</given-names></name></person-group><article-title>Competitive intelligence and patent analysis in drug discovery</article-title>. <source>Drug Discov. Today Technol.</source><year>2005</year>; <volume>2</volume>:<fpage>211</fpage>–<lpage>215</lpage>.<pub-id pub-id-type="pmid">24981938</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhavoronkov</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ivanenkov</surname><given-names>Y.A.</given-names></name>, <name name-style="western"><surname>Aliper</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Veselov</surname><given-names>M.S.</given-names></name>, <name name-style="western"><surname>Aladinskiy</surname><given-names>V.A.</given-names></name>, <name name-style="western"><surname>Aladinskaya</surname><given-names>A.V.</given-names></name>, <name name-style="western"><surname>Terentiev</surname><given-names>V.A.</given-names></name>, <name name-style="western"><surname>Polykovskiy</surname><given-names>D.A.</given-names></name>, <name name-style="western"><surname>Kuznetsov</surname><given-names>M.D.</given-names></name>, <name name-style="western"><surname>Asadulaev</surname><given-names>A.</given-names></name><etal>et al</etal>.</person-group><article-title>Deep learning enables rapid identification of potent DDR1 kinase inhibitors</article-title>. <source>Nat. Biotechnol.</source><year>2019</year>; <volume>37</volume>:<fpage>1038</fpage>–<lpage>1040</lpage>.<pub-id pub-id-type="pmid">31477924</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rukov</surname><given-names>J.L.</given-names></name>, <name name-style="western"><surname>Shomron</surname><given-names>N.</given-names></name></person-group><article-title>MicroRNA pharmacogenomics: post-transcriptional regulation of drug response</article-title>. <source>Trends Mol. Med.</source><year>2011</year>; <volume>17</volume>:<fpage>412</fpage>–<lpage>423</lpage>.<pub-id pub-id-type="pmid">21652264</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohri</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Nakajima</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Takagi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Komagata</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Yokoi</surname><given-names>T.</given-names></name></person-group><article-title>MicroRNA regulates human vitamin D receptor</article-title>. <source>Int. J. Cancer</source>. <year>2009</year>; <volume>125</volume>:<fpage>1328</fpage>–<lpage>1333</lpage>.<pub-id pub-id-type="pmid">19437538</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>P.J.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Mishra</surname><given-names>P.J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Humeniuk</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Banerjee</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Merlino</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Ju</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bertino</surname><given-names>J.R.</given-names></name></person-group><article-title>MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism</article-title>. <source>PLoS One</source>. <year>2009</year>; <volume>4</volume>:<fpage>e8445</fpage>.<pub-id pub-id-type="pmid">20041160</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pichler</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Calin</surname><given-names>G.A.</given-names></name></person-group><article-title>MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients</article-title>. <source>Br. J. Cancer</source>. <year>2015</year>; <volume>113</volume>:<fpage>569</fpage>–<lpage>573</lpage>.<pub-id pub-id-type="pmid">26158421</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uhlmann</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Mannsperger</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J.D.</given-names></name>, <name name-style="western"><surname>Horvat</surname><given-names>E.A.</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kublbeck</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Henjes</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Tschulena</surname><given-names>U.</given-names></name>, <name name-style="western"><surname>Zweig</surname><given-names>K.</given-names></name><etal>et al</etal>.</person-group><article-title>Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer</article-title>. <source>Mol. Syst. Biol.</source><year>2012</year>; <volume>8</volume>:<fpage>570</fpage>.<pub-id pub-id-type="pmid">22333974</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morquette</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Juzwik</surname><given-names>C.A.</given-names></name>, <name name-style="western"><surname>Drake</surname><given-names>S.S.</given-names></name>, <name name-style="western"><surname>Charabati</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Lecuyer</surname><given-names>M.A.</given-names></name>, <name name-style="western"><surname>Galloway</surname><given-names>D.A.</given-names></name>, <name name-style="western"><surname>Dumas</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>de Faria Junior</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Paradis-Isler</surname><given-names>N.</given-names></name><etal>et al</etal>.</person-group><article-title>MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis</article-title>. <source>Brain</source>. <year>2019</year>; <volume>142</volume>:<fpage>2979</fpage>–<lpage>2995</lpage>.<pub-id pub-id-type="pmid">31412103</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandrasekaran</surname><given-names>A.R.</given-names></name>, <name name-style="western"><surname>MacIsaac</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Dey</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Levchenko</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Andres</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Dey</surname><given-names>B.K.</given-names></name>, <name name-style="western"><surname>Halvorsen</surname><given-names>K.</given-names></name></person-group><article-title>Cellular microRNA detection with miRacles: microRNA- activated conditional looping of engineered switches</article-title>. <source>Sci. Adv.</source><year>2019</year>; <volume>5</volume>:<fpage>eaau9443</fpage>.<pub-id pub-id-type="pmid">30891499</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Androvic</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Valihrach</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Elling</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sjoback</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Kubista</surname><given-names>M.</given-names></name></person-group><article-title>Two-tailed RT-qPCR: a novel method for highly accurate miRNA quantification</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>; <volume>45</volume>:<fpage>e144</fpage>.<pub-id pub-id-type="pmid">28911110</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franchini</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Xiong</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Fruciano</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>R.F.</given-names></name>, <name name-style="western"><surname>Woltering</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Hulsey</surname><given-names>C.D.</given-names></name>, <name name-style="western"><surname>Meyer</surname><given-names>A.</given-names></name></person-group><article-title>MicroRNA gene regulation in extremely young and parallel adaptive radiations of crater lake cichlid fish</article-title>. <source>Mol. Biol. Evol.</source><year>2019</year>; <volume>36</volume>:<fpage>2498</fpage>–<lpage>2511</lpage>.</mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatr-Aryamontri</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Oughtred</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Boucher</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Rust</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kolas</surname><given-names>N.K.</given-names></name>, <name name-style="western"><surname>O’Donnell</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Oster</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Theesfeld</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sellam</surname><given-names>A.</given-names></name><etal>et al</etal>.</person-group><article-title>The BioGRID interaction database: 2017 update</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>; <volume>45</volume>:<fpage>D369</fpage>–<lpage>D379</lpage>.<pub-id pub-id-type="pmid">27980099</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salwinski</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>C.S.</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>A.J.</given-names></name>, <name name-style="western"><surname>Pettit</surname><given-names>F.K.</given-names></name>, <name name-style="western"><surname>Bowie</surname><given-names>J.U.</given-names></name>, <name name-style="western"><surname>Eisenberg</surname><given-names>D.</given-names></name></person-group><article-title>The database of interacting proteins: 2004 update</article-title>. <source>Nucleic Acids Res.</source><year>2004</year>; <volume>32</volume>:<fpage>D449</fpage>–<lpage>D451</lpage>.<pub-id pub-id-type="pmid">14681454</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heguy</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>A.A.</given-names></name>, <name name-style="western"><surname>Haley</surname><given-names>J.D.</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>D.E.</given-names></name>, <name name-style="western"><surname>Foulkes</surname><given-names>J.G.</given-names></name></person-group><article-title>Gene expression as a target for new drug discovery</article-title>. <source>Gene Expr.</source><year>1995</year>; <volume>4</volume>:<fpage>337</fpage>–<lpage>344</lpage>.<pub-id pub-id-type="pmid">7549465</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dang</surname><given-names>C.V.</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>E.P.</given-names></name>, <name name-style="western"><surname>Shokat</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Soucek</surname><given-names>L.</given-names></name></person-group><article-title>Drugging the ‘undruggable’ cancer targets</article-title>. <source>Nat. Rev. Cancer</source>. <year>2017</year>; <volume>17</volume>:<fpage>502</fpage>–<lpage>508</lpage>.<pub-id pub-id-type="pmid">28643779</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kessler</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Gmachl</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Mantoulidis</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>L.J.</given-names></name>, <name name-style="western"><surname>Zoephel</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mayer</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Gollner</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Covini</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Fischer</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Gerstberger</surname><given-names>T.</given-names></name><etal>et al</etal>.</person-group><article-title>Drugging an undruggable pocket on KRAS</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2019</year>; <volume>116</volume>:<fpage>15823</fpage>–<lpage>15829</lpage>.<pub-id pub-id-type="pmid">31332011</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wingender</surname><given-names>E.</given-names></name></person-group><article-title>The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation</article-title>. <source>Brief. Bioinform.</source><year>2008</year>; <volume>9</volume>:<fpage>326</fpage>–<lpage>332</lpage>.<pub-id pub-id-type="pmid">18436575</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matys</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Kel-Margoulis</surname><given-names>O.V.</given-names></name>, <name name-style="western"><surname>Fricke</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Liebich</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Land</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Barre-Dirrie</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Reuter</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Chekmenev</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Krull</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hornischer</surname><given-names>K.</given-names></name><etal>et al</etal>.</person-group><article-title>TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes</article-title>. <source>Nucleic Acids Res.</source><year>2006</year>; <volume>34</volume>:<fpage>D108</fpage>–<lpage>D110</lpage>.<pub-id pub-id-type="pmid">16381825</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawauchi</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Nobori</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Hashimoto</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Adachi</surname><given-names>M.T.</given-names></name>, <name name-style="western"><surname>Noda</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Sunamori</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kitajima</surname><given-names>S.</given-names></name></person-group><article-title>Transcriptional repressor activating transcription factor 3 protects human umbilical vein endothelial cells from tumor necrosis factor-alpha-induced apoptosis through down-regulation of p53 transcription</article-title>. <source>J. Biol. Chem.</source><year>2002</year>; <volume>277</volume>:<fpage>39025</fpage>–<lpage>39034</lpage>.<pub-id pub-id-type="pmid">12161427</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>C.L.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Vega</surname><given-names>V.B.</given-names></name>, <name name-style="western"><surname>Chiu</surname><given-names>K.P.</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Shahab</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Yong</surname><given-names>H.C.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Weng</surname><given-names>Z.</given-names></name><etal>et al</etal>.</person-group><article-title>A global map of p53 transcription-factor binding sites in the human genome</article-title>. <source>Cell</source>. <year>2006</year>; <volume>124</volume>:<fpage>207</fpage>–<lpage>219</lpage>.<pub-id pub-id-type="pmid">16413492</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neish</surname><given-names>A.S.</given-names></name>, <name name-style="western"><surname>Read</surname><given-names>M.A.</given-names></name>, <name name-style="western"><surname>Thanos</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Pine</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Maniatis</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Collins</surname><given-names>T.</given-names></name></person-group><article-title>Endothelial interferon regulatory factor 1 cooperates with NF-kappa B as a transcriptional activator of vascular cell adhesion molecule 1</article-title>. <source>Mol. Cell Biol.</source><year>1995</year>; <volume>15</volume>:<fpage>2558</fpage>–<lpage>2569</lpage>.<pub-id pub-id-type="pmid">7537851</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gagniuc</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Ionescu-Tirgoviste</surname><given-names>C.</given-names></name></person-group><article-title>Gene promoters show chromosome-specificity and reveal chromosome territories in humans</article-title>. <source>BMC Genomics</source>. <year>2013</year>; <volume>14</volume>:<fpage>278</fpage>.<pub-id pub-id-type="pmid">23617842</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pennacchio</surname><given-names>L.A.</given-names></name>, <name name-style="western"><surname>Bickmore</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Dean</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Nobrega</surname><given-names>M.A.</given-names></name>, <name name-style="western"><surname>Bejerano</surname><given-names>G.</given-names></name></person-group><article-title>Enhancers: five essential questions</article-title>. <source>Nat. Rev. Genet.</source><year>2013</year>; <volume>14</volume>:<fpage>288</fpage>–<lpage>295</lpage>.<pub-id pub-id-type="pmid">23503198</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maston</surname><given-names>G.A.</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>S.K.</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>M.R.</given-names></name></person-group><article-title>Transcriptional regulatory elements in the human genome</article-title>. <source>Annu. Rev. Genomics Hum. Genet.</source><year>2006</year>; <volume>7</volume>:<fpage>29</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">16719718</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <label>59.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopkins</surname><given-names>A.L.</given-names></name></person-group><article-title>Network pharmacology: the next paradigm in drug discovery</article-title>. <source>Nat. Chem. Biol.</source><year>2008</year>; <volume>4</volume>:<fpage>682</fpage>–<lpage>690</lpage>.<pub-id pub-id-type="pmid">18936753</pub-id></mixed-citation>
    </ref>
    <ref id="B60">
      <label>60.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Rzhetsky</surname><given-names>A.</given-names></name></person-group><article-title>Quantitative systems-level determinants of human genes targeted by successful drugs</article-title>. <source>Genome Res.</source><year>2008</year>; <volume>18</volume>:<fpage>206</fpage>–<lpage>213</lpage>.<pub-id pub-id-type="pmid">18083776</pub-id></mixed-citation>
    </ref>
    <ref id="B61">
      <label>61.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.H.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.X.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>J.J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.X.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>J.B.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>C.Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F.C.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>W.W.</given-names></name><etal>et al</etal>.</person-group><article-title>Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs</article-title>. <source>Brief. Bioinform.</source><year>2019</year>; <comment>doi:10.1093/bib/bby130</comment>.</mixed-citation>
    </ref>
    <ref id="B62">
      <label>62.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oughtred</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Stark</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Breitkreutz</surname><given-names>B.J.</given-names></name>, <name name-style="western"><surname>Rust</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Boucher</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kolas</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>O’Donnell</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>McAdam</surname><given-names>R.</given-names></name><etal>et al</etal>.</person-group><article-title>The BioGRID interaction database: 2019 update</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D529</fpage>–<lpage>D541</lpage>.<pub-id pub-id-type="pmid">30476227</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <label>63.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cousins</surname><given-names>K.R.</given-names></name></person-group><article-title>Computer review of ChemDraw ultra 12.0</article-title>. <source>J. Am. Chem. Soc.</source><year>2011</year>; <volume>133</volume>:<fpage>8388</fpage>.<pub-id pub-id-type="pmid">21561109</pub-id></mixed-citation>
    </ref>
    <ref id="B64">
      <label>64.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajusz</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Racz</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Heberger</surname><given-names>K.</given-names></name></person-group><article-title>Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations</article-title>. <source>J. Cheminform.</source><year>2015</year>; <volume>7</volume>:<fpage>20</fpage>.<pub-id pub-id-type="pmid">26052348</pub-id></mixed-citation>
    </ref>
    <ref id="B65">
      <label>65.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lancet</surname><given-names>T.</given-names></name></person-group><article-title>ICD-11</article-title>. <source>Lancet</source>. <year>2019</year>; <volume>393</volume>:<fpage>2275</fpage>.<pub-id pub-id-type="pmid">31180012</pub-id></mixed-citation>
    </ref>
    <ref id="B66">
      <label>66.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miotto</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Kidd</surname><given-names>B.A.</given-names></name>, <name name-style="western"><surname>Dudley</surname><given-names>J.T.</given-names></name></person-group><article-title>Deep patient: an unsupervised representation to predict the future of patients from the electronic health records</article-title>. <source>Sci. Rep.</source><year>2016</year>; <volume>6</volume>:<fpage>26094</fpage>.<pub-id pub-id-type="pmid">27185194</pub-id></mixed-citation>
    </ref>
    <ref id="B67">
      <label>67.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><etal>et al</etal>.</person-group><article-title>Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery</article-title>. <source>Nucleic Acids Res.</source><year>2012</year>; <volume>40</volume>:<fpage>D1128</fpage>–<lpage>D1136</lpage>.<pub-id pub-id-type="pmid">21948793</pub-id></mixed-citation>
    </ref>
    <ref id="B68">
      <label>68.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davila</surname><given-names>M.L.</given-names></name>, <name name-style="western"><surname>Riviere</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Bartido</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Curran</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>S.S.</given-names></name>, <name name-style="western"><surname>Stefanski</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Borquez-Ojeda</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Olszewska</surname><given-names>M.</given-names></name><etal>et al</etal>.</person-group><article-title>Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia</article-title>. <source>Sci. Transl. Med.</source><year>2014</year>; <volume>6</volume>:<fpage>224ra225</fpage>.</mixed-citation>
    </ref>
    <ref id="B69">
      <label>69.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullard</surname><given-names>A.</given-names></name></person-group><article-title>2017 FDA drug approvals</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2018</year>; <volume>17</volume>:<fpage>150</fpage>.</mixed-citation>
    </ref>
    <ref id="B70">
      <label>70.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zarin</surname><given-names>D.A.</given-names></name>, <name name-style="western"><surname>Tse</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>R.J.</given-names></name>, <name name-style="western"><surname>Carr</surname><given-names>S.</given-names></name></person-group><article-title>Trial reporting in ClinicalTrials.gov - the final rule</article-title>. <source>N. Engl. J. Med.</source><year>2016</year>; <volume>375</volume>:<fpage>1998</fpage>–<lpage>2004</lpage>.<pub-id pub-id-type="pmid">27635471</pub-id></mixed-citation>
    </ref>
    <ref id="B71">
      <label>71.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway</article-title>. <source>J. Med. Chem.</source><year>2019</year>; <volume>62</volume>:<fpage>1715</fpage>–<lpage>1730</lpage>.<pub-id pub-id-type="pmid">30247903</pub-id></mixed-citation>
    </ref>
    <ref id="B72">
      <label>72.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title>. <source>Nat. Rev. Cancer</source>. <year>2012</year>; <volume>12</volume>:<fpage>252</fpage>–<lpage>264</lpage>.<pub-id pub-id-type="pmid">22437870</pub-id></mixed-citation>
    </ref>
    <ref id="B73">
      <label>73.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomaselli</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Lucidi</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Rotili</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Mai</surname><given-names>A.</given-names></name></person-group><article-title>Epigenetic polypharmacology: a new frontier for epi-drug discovery</article-title>. <source>Med. Res. Rev.</source><year>2019</year>; <comment>doi:10.1002/med.21600</comment>.</mixed-citation>
    </ref>
    <ref id="B74">
      <label>74.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.X.</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>L.</given-names></name><etal>et al</etal>.</person-group><article-title>Determining the balance between drug efficacy and safety by the network and biological system profile of its therapeutic target</article-title>. <source>Front. Pharmacol.</source><year>2018</year>; <volume>9</volume>:<fpage>1245</fpage>.<pub-id pub-id-type="pmid">30429792</pub-id></mixed-citation>
    </ref>
    <ref id="B75">
      <label>75.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hiatt</surname><given-names>W.R.</given-names></name>, <name name-style="western"><surname>Armstrong</surname><given-names>E.J.</given-names></name>, <name name-style="western"><surname>Larson</surname><given-names>C.J.</given-names></name>, <name name-style="western"><surname>Brass</surname><given-names>E.P.</given-names></name></person-group><article-title>Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease</article-title>. <source>Circ. Res.</source><year>2015</year>; <volume>116</volume>:<fpage>1527</fpage>–<lpage>1539</lpage>.<pub-id pub-id-type="pmid">25908726</pub-id></mixed-citation>
    </ref>
    <ref id="B76">
      <label>76.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Lou</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group><article-title>Consistent gene signature of schizophrenia identified by a novel feature selection strategy from comprehensive sets of transcriptomic data</article-title>. <source>Brief. Bioinform.</source><year>2019</year>; <comment>doi:10.1093/bib/bbz049</comment>.</mixed-citation>
    </ref>
    <ref id="B77">
      <label>77.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>C.W.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>Y.J.</given-names></name>, <name name-style="western"><surname>Reid</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Parker</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Pavlopoulos</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Dischinger</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Graveel</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Aguirre</surname><given-names>A.J.</given-names></name>, <name name-style="western"><surname>Steensma</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Haigis</surname><given-names>K.M.</given-names></name><etal>et al</etal>.</person-group><article-title>Isoform-specific destabilization of the active site reveals a molecular mechanism of intrinsic activation of KRas G13D</article-title>. <source>Cell Rep.</source><year>2019</year>; <volume>28</volume>:<fpage>1538</fpage>–<lpage>1550</lpage>.<pub-id pub-id-type="pmid">31390567</pub-id></mixed-citation>
    </ref>
    <ref id="B78">
      <label>78.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name></person-group><article-title>What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation</article-title>. <source>ACS Chem. Neurosci.</source><year>2018</year>; <volume>9</volume>:<fpage>1128</fpage>–<lpage>1140</lpage>.<pub-id pub-id-type="pmid">29300091</pub-id></mixed-citation>
    </ref>
    <ref id="B79">
      <label>79.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><etal>et al</etal>.</person-group><article-title>VARIDT 1.0: variability of drug transporter database</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <comment>doi:10.1093/nar/gkz779</comment>.</mixed-citation>
    </ref>
    <ref id="B80">
      <label>80.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuenzi</surname><given-names>B.M.</given-names></name>, <name name-style="western"><surname>Remsing Rix</surname><given-names>L.L.</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>P.A.</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Kinose</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Bryant</surname><given-names>A.T.</given-names></name>, <name name-style="western"><surname>Boyle</surname><given-names>T.A.</given-names></name>, <name name-style="western"><surname>Koomen</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Haura</surname><given-names>E.B.</given-names></name>, <name name-style="western"><surname>Rix</surname><given-names>U.</given-names></name></person-group><article-title>Polypharmacology-based ceritinib repurposing using integrated functional proteomics</article-title>. <source>Nat. Chem. Biol.</source><year>2017</year>; <volume>13</volume>:<fpage>1222</fpage>–<lpage>1231</lpage>.<pub-id pub-id-type="pmid">28991240</pub-id></mixed-citation>
    </ref>
    <ref id="B81">
      <label>81.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Rossi</surname><given-names>J.</given-names></name></person-group><article-title>Aptamers as targeted therapeutics: current potential and challenges</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2017</year>; <volume>16</volume>:<fpage>181</fpage>–<lpage>202</lpage>.<pub-id pub-id-type="pmid">27807347</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
